Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Morishima T, Ikai H, Imanaka Y. Cost-effectiveness analysis of omalizumab for the treatment of severe asthma in Japan and the value of responder prediction methods based on a multinational trial. Value in Health Regional Issues 2013; 2(1): 29-36 Indexing Status Subject indexing assigned by CRD MeSH Administration, Inhalation; Anti-Asthmatic Agents; Antibodies, Monoclonal; Asthma; Humans; Japan AccessionNumber 22013021756 Date bibliographic record published 11/06/2013 |